Sagimet Biosciences Inc
NASDAQ:SGMT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.47
18.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sagimet Biosciences Inc
Sagimet Biosciences Inc
Pre-Tax Income
Sagimet Biosciences Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sagimet Biosciences Inc
NASDAQ:SGMT
|
Pre-Tax Income
-$27.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$7.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
19%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$176m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-34%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$259.6m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
Sagimet Biosciences Inc
Glance View
Sagimet Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). In addition to NASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase II clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
See Also
What is Sagimet Biosciences Inc's Pre-Tax Income?
Pre-Tax Income
-27.9m
USD
Based on the financial report for Dec 31, 2023, Sagimet Biosciences Inc's Pre-Tax Income amounts to -27.9m USD.
What is Sagimet Biosciences Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-35%
Over the last year, the Pre-Tax Income growth was 9%. The average annual Pre-Tax Income growth rates for Sagimet Biosciences Inc have been -35% over the past three years .
You don't have any saved screeners yet
